Showing 40,041 - 40,060 results of 110,994 for search '(( 5 ((((we decrease) OR (mean decrease))) OR (a decrease)) ) OR ( a point decrease ))', query time: 2.14s Refine Results
  1. 40041

    Softening of PEO–LiTFSI/LLZTO Composite Polymer Electrolytes for Solid-State Batteries under Cyclic Compression by Dan-il Yoon (16958498)

    Published 2023
    “…While the extent of softening was similar regardless of particle size, CPEs with 500 nm particles exhibited a significant reduction in ionic conductivity after cyclic compression (1.4 × 10<sup>–7</sup> ± 2.3 × 10<sup>–8</sup> vs 1.1 × 10<sup>–7</sup> ± 2.0 × 10<sup>–8</sup> S/cm, mean ± standard deviation, <i>n</i> = 4), whereas there was no significant change in ionic conductivity for CPEs with 5 μm particles. …”
  2. 40042

    Softening of PEO–LiTFSI/LLZTO Composite Polymer Electrolytes for Solid-State Batteries under Cyclic Compression by Dan-il Yoon (16958498)

    Published 2023
    “…While the extent of softening was similar regardless of particle size, CPEs with 500 nm particles exhibited a significant reduction in ionic conductivity after cyclic compression (1.4 × 10<sup>–7</sup> ± 2.3 × 10<sup>–8</sup> vs 1.1 × 10<sup>–7</sup> ± 2.0 × 10<sup>–8</sup> S/cm, mean ± standard deviation, <i>n</i> = 4), whereas there was no significant change in ionic conductivity for CPEs with 5 μm particles. …”
  3. 40043

    Softening of PEO–LiTFSI/LLZTO Composite Polymer Electrolytes for Solid-State Batteries under Cyclic Compression by Dan-il Yoon (16958498)

    Published 2023
    “…While the extent of softening was similar regardless of particle size, CPEs with 500 nm particles exhibited a significant reduction in ionic conductivity after cyclic compression (1.4 × 10<sup>–7</sup> ± 2.3 × 10<sup>–8</sup> vs 1.1 × 10<sup>–7</sup> ± 2.0 × 10<sup>–8</sup> S/cm, mean ± standard deviation, <i>n</i> = 4), whereas there was no significant change in ionic conductivity for CPEs with 5 μm particles. …”
  4. 40044

    Hemostasis in a rat liver laceration model. by Seiji Komatsu (601990)

    Published 2014
    “…(B) Bleeding decreased immediately following application of the 1.5% (w/v) SPG-178 hydrogel to the bleeding surface. …”
  5. 40045

    Paf1, but not Ski8, depletion leads to strong accumulation of PolII downstream of the TSS of genes with up-regulated intronic APA. by Yan Yang (33204)

    Published 2016
    “…<p><b>(A)</b> The average enrichment profiles of PolII after depletion of Paf1 or Ski8. …”
  6. 40046

    Prolonged Glycemic Adaptation Following Transition From a Low- to High-Carbohydrate Diet: A Randomized Controlled Feeding Trial by Lisa T Jansen (11876618)

    Published 2022
    “…</p> <p><b>Results: </b> Glucose metrics continued to decline after week 1 in HC-Starch and HC‑Sugar (p<0.05), but not VLC. From weeks 2-5, fasting and 2-hr glucose (mmol/L per week) decreased in HC-Starch (fasting: -0.10, p=0.001; 2-hr: -0.10, p=0.04). …”
  7. 40047
  8. 40048
  9. 40049

    PyrrolylBODIPYs: Syntheses, Properties, and Application as Environment-Sensitive Fluorescence Probes by Changjiang Yu (319189)

    Published 2017
    “…These pyrrolylBODIPYs generally show intense absorption (centered at 570–624 nm) and fluorescence emission (582–654 nm) in nonpolar solvents. A gradual decrease in the fluorescence intensity was observed for these dyes with the increase in solvent dipolar moment, which combines with the red to far-red absorption/emission, rendering these pyrrolylBODIPYs potential applications as environment-sensitive fluorescence probes as demonstrated in this work for bovine serum albumin.…”
  10. 40050

    PyrrolylBODIPYs: Syntheses, Properties, and Application as Environment-Sensitive Fluorescence Probes by Changjiang Yu (319189)

    Published 2017
    “…These pyrrolylBODIPYs generally show intense absorption (centered at 570–624 nm) and fluorescence emission (582–654 nm) in nonpolar solvents. A gradual decrease in the fluorescence intensity was observed for these dyes with the increase in solvent dipolar moment, which combines with the red to far-red absorption/emission, rendering these pyrrolylBODIPYs potential applications as environment-sensitive fluorescence probes as demonstrated in this work for bovine serum albumin.…”
  11. 40051

    Impact Evaluation of a System-Wide Chronic Disease Management Program on Health Service Utilisation: A Propensity-Matched Cohort Study by Laurent Billot (838453)

    Published 2016
    “…These components were broadly prescribed by the head office of NSW Health, which funded the program, and were implemented by regional health services (local health districts) in ways that best suited their own history, environment, workforce, and patient need. We used a propensity-matched cohort study to evaluate health service utilisation after enrolment in the CDMP.…”
  12. 40052

    Celastrol is a potent p536 inhibitor. by Longjiang Shao (385841)

    Published 2013
    “…(<b>B</b>) VCaP cells were treated with different concentration of celastrol for 2 h. Significant decreased p536 expression was seen in all groups by western blot, including the lowest concentration group of 0.05 µM, strongly suggesting Celastrol is a potent p536 inhibitor. β-actin was the control.…”
  13. 40053

    Copeptin as a Serum Biomarker of Febrile Seizures by Benjamin Stöcklin (727398)

    Published 2015
    “…</p><p>Methods</p><p>This was a prospective emergency-setting cross-sectional study of 161 children between six months and five years of age. …”
  14. 40054

    Light-Reconfiguring Inhomogeneous Soft Helical Pitch with Fatigue Resistance and Reversibility by Mengqi Li (2608237)

    Published 2022
    “…For the working model, the intrinsic chiral photoswitch <b>LBC5</b> is employed as an actuator to modulate the helical pitch length, which is proportional to the irradiation intensity, and the unique broadband absorbance photo-modulator <b>BTA-C5</b> is incorporated as an attenuator of the transmitted light to decrease its intensity along the sample thickness, therefore successfully adding another controlled DOF on the pitch length distribution (i.e., homogeneous or inhomogeneous) apart from the common soft helix with only a single DOF on the pitch length. …”
  15. 40055

    Light-Reconfiguring Inhomogeneous Soft Helical Pitch with Fatigue Resistance and Reversibility by Mengqi Li (2608237)

    Published 2022
    “…For the working model, the intrinsic chiral photoswitch <b>LBC5</b> is employed as an actuator to modulate the helical pitch length, which is proportional to the irradiation intensity, and the unique broadband absorbance photo-modulator <b>BTA-C5</b> is incorporated as an attenuator of the transmitted light to decrease its intensity along the sample thickness, therefore successfully adding another controlled DOF on the pitch length distribution (i.e., homogeneous or inhomogeneous) apart from the common soft helix with only a single DOF on the pitch length. …”
  16. 40056

    Light-Reconfiguring Inhomogeneous Soft Helical Pitch with Fatigue Resistance and Reversibility by Mengqi Li (2608237)

    Published 2022
    “…For the working model, the intrinsic chiral photoswitch <b>LBC5</b> is employed as an actuator to modulate the helical pitch length, which is proportional to the irradiation intensity, and the unique broadband absorbance photo-modulator <b>BTA-C5</b> is incorporated as an attenuator of the transmitted light to decrease its intensity along the sample thickness, therefore successfully adding another controlled DOF on the pitch length distribution (i.e., homogeneous or inhomogeneous) apart from the common soft helix with only a single DOF on the pitch length. …”
  17. 40057

    Light-Reconfiguring Inhomogeneous Soft Helical Pitch with Fatigue Resistance and Reversibility by Mengqi Li (2608237)

    Published 2022
    “…For the working model, the intrinsic chiral photoswitch <b>LBC5</b> is employed as an actuator to modulate the helical pitch length, which is proportional to the irradiation intensity, and the unique broadband absorbance photo-modulator <b>BTA-C5</b> is incorporated as an attenuator of the transmitted light to decrease its intensity along the sample thickness, therefore successfully adding another controlled DOF on the pitch length distribution (i.e., homogeneous or inhomogeneous) apart from the common soft helix with only a single DOF on the pitch length. …”
  18. 40058

    Light-Reconfiguring Inhomogeneous Soft Helical Pitch with Fatigue Resistance and Reversibility by Mengqi Li (2608237)

    Published 2022
    “…For the working model, the intrinsic chiral photoswitch <b>LBC5</b> is employed as an actuator to modulate the helical pitch length, which is proportional to the irradiation intensity, and the unique broadband absorbance photo-modulator <b>BTA-C5</b> is incorporated as an attenuator of the transmitted light to decrease its intensity along the sample thickness, therefore successfully adding another controlled DOF on the pitch length distribution (i.e., homogeneous or inhomogeneous) apart from the common soft helix with only a single DOF on the pitch length. …”
  19. 40059

    Light-Reconfiguring Inhomogeneous Soft Helical Pitch with Fatigue Resistance and Reversibility by Mengqi Li (2608237)

    Published 2022
    “…For the working model, the intrinsic chiral photoswitch <b>LBC5</b> is employed as an actuator to modulate the helical pitch length, which is proportional to the irradiation intensity, and the unique broadband absorbance photo-modulator <b>BTA-C5</b> is incorporated as an attenuator of the transmitted light to decrease its intensity along the sample thickness, therefore successfully adding another controlled DOF on the pitch length distribution (i.e., homogeneous or inhomogeneous) apart from the common soft helix with only a single DOF on the pitch length. …”
  20. 40060

    Supplementary Material for: The Association of Proteinuria Target Achievement Timing and Stability with Adverse Kidney Outcomes Among Patients with IgA Nephropathy: A Cohort Study by figshare admin karger (2628495)

    Published 2025
    “…We analyzed the association between those three metrics and the composite kidney outcome, which was defined as the first occurrence of either end-stage kidney disease (ESKD or a >50% decrease in eGFR from baseline. …”